Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
<h4>Background</h4>Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov N...
Saved in:
| Main Authors: | Gerald Goh, Ramona Schmid, Kelly Guiver, Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock-Ah Im, Sung-Bae Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn, Neil Spector, Thomas Yau, Mehdi Afrit, Slim Ben Ahmed, Stephen R Johnston, Neil Gibson, Martina Uttenreuther-Fischer, Javier Herrero, Charles Swanton |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-12-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.1002136 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis
by: Aurelia Robert, et al.
Published: (2025-08-01) -
Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer
by: Huang JY, et al.
Published: (2025-06-01) -
Draw(her)
by: Amélie Lemieux
Published: (2019-11-01) -
In Her Words:
by: Oriana Quaglietta Bernal
Published: (2022-02-01) -
Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
by: Marianne Nordlund Broughton, et al.
Published: (2017-06-01)